Introduction
============

Glioblastoma (GBM) is the most common and aggressive human brain tumor characterized by local invasion, microvascular proliferation, and therapeutic resistance ([@B33]). Despite therapeutic advances in the last several decades, the outcome of GBM patients still poor with a median survival of only 12--15 months ([@B49]). Glioblastoma stem cells (GSCs) correspond to a tumor cell subpopulation, display extensive self-renewal, multilineage differentiation, and propagation of tumors ([@B45]; [@B3]; [@B16]; [@B34]). Considerable evidence have proved that GSCs are responsible for tumor angiogenesis, immune evasion, therapeutic resistance, and tumor recurrence ([@B3]; [@B51]). Therefore, treatments that improve targeting of GSCs are urgent needed to be provided.

Accumulating evidence showed that different manners of programmed cell death could trigger different biological events. Autophagy, also known as type II programmed cell death, can induce programmed cell death which further propels chemotherapy and/or radiotherapy-mediated cytotoxicity in apoptosis-resistant tumor cells ([@B54]). The role of autophagy in various physiological and pathological processes is currently being investigated. Drug-induced autophagy has been corroborated to have anti-inflammatory and anti-tumor effects, and it has been confirmed that the autophagic response could strengthen the anti-tumor effects of drugs ([@B8]; [@B1]). Therapeutic studies have shown that glioma cells could undergo autophagy by drugs, which triggers autophagic cell death. Clinical trials proved that temozolomide (TMZ), which achieved better curative effects in the patients with apoptosis-resistant GBM ([@B18]), could induce autophagy in GBM cells as well ([@B27]). Valproic acid (VPA) was also confirmed to be able to cause cell death of glioma cell lines by inducing autophagy ([@B13]). Recent study also showed that cannabidiol inhibits GSCs proliferation by inducing autophagy in a transient receptor potential vanilloid-2(TRPV2)-dependent manner ([@B31]). Taken together, inducing autophagic death might be one of the main mechanisms of anti-neoplastic drugs in human GBM cells and GSCs.

Endothelial-monocyte-activating polypeptide II (EMAP II) is a protein extrated from methylcholantherene A (Meth A) transformed fibrosarcoma ([@B19]). Low-dose EMAP II has been confirmed to increase the blood-tumor barrier (BTB) permeability by opening tight junction (TJ) via Rho A, PKC or other signal pathways ([@B26], [@B25]; [@B55]). Furthermore, EMAP II has been confirmed as a component of the immunosuppressive pathway in several solid tumors ([@B29],[@B30]; [@B11]). EMAP II could suppress the growth of primary and metastatic tumors and induce apoptosis in growing endothelial cells ([@B39]). Elevated EMAP II expression was associated with lymphocyte apoptosis and lack of metastases in colon cancer patients ([@B46]). The *in vivo* study reported that EMAP II attenuated the primary tumor growth of rat C6 glioma cells ([@B41]). In pancreatic cancer, EMAP II alone or in combination with bortezomib have anti-proliferative and pro-apoptotic effects, and significantly reduced B-cell lymphoma-2 (Bcl-2) expression ([@B2]). Beclin-1 was found to induce autophagy, and Bcl-2 could inhibit its function by binding its BH~3~ domain ([@B14]), suggesting that EMAP II might induce autophagy. Therefore, whether EMAP-II induces the autophagy of human GBM cells and GSCs needs to be explored urgently.

In the present study, we investigated whether EMAP II induce cell autophagy in human GBM cells and GSCs, and its potential mechanisms. Further, we examined the effect of the combination of EMAP II with rapamycin on biological behaviors of human GBM cells and GSCs *in vitro* and *in vivo*.

Materials and Methods {#s1}
=====================

Reagents
--------

Dulbecco's modified eagle's medium (DMEM), fetal bovine serum (FBS), DMEM/F-12 medium and basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), 2% B27 and MitoTracker Deep Red FM were purchased from Life Technologies Corporation (Carlsbad, CA, USA). EMAP II, rapamycin, dimethyl sulfoxide (DMSO), 3-methyl adenine (3-MA), Z-VAD-fmk (Z-VAD), tauroursodeoxycholate (TUDC), and laminin were purchased from Sigma--Aldrich (St. Louis, MO, USA). Cell counting kit-8 (CCK8), DAPI, Alexa Fluor 488, Alexa Fluor 555, and BCA protein assay kit were purchased from Beyotime Institute of Biotechnology (Jiangsu, China). 5,5,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-benzimidazol-carbo-cyanine iodide (JC-1) apoptosis detection kits were purchased from Becton Dickinson Bioscience (San Jose, CA, USA). IGF-1 was purchased from PeproTech (St.Louis, MO, USA). Primary antibodies against microtubule-associated protein 1 light chain 3 (LC3, ab63817) and p62/SQSMT1 (ab56416) were purchased from Abcam (Cambridge, MA, USA). Primary antibodies against p-PI3K (\#4228), PI3K (\#4257), p-Akt (Ser473) (\#9271), Akt (\#9272), p-mTOR (Ser 2448) (\#2971), mTOR (\#2972), GRP78 (\#3183), p-eIF2α (\#3398), eIF2α (\#5324), and CHOP (\#5554) antibodies were from Cell Signaling Technology (Beverly, MA, USA). Anti-GAPDH (sc-365062) and the secondary antibodies conjugated with horseradish peroxidase were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibodies against TOMM20 (612278), TIMM23 (611222), and Matrigel were purchased from BD Biosciences (Franklin Lakes, NJ, USA).

Cell Culture and Treatment Conditions
-------------------------------------

Human GBM cell lines (U87 and U118) were obtained from Shanghai Institutes for Biological Sciences Cell Resource Center and were cultured in DMEM with 10% FBS in a humidified atmosphere of 5% CO~2~ at 37°C. GSCs were isolated from fresh surgical specimens of human GBM tissues following the procedures as described previously ([@B44]; [@B57]). GSCs were maintained in DMEM/F-12 medium supplemented with bFGF (20 ng/ml), EGF (20 ng/ml) and 2% B27. The five independent GSCs were isolated from 5 GBM patients. All the patients provided written informed consent, and the study was approved by the Ethics Committee of Shengjing Hospital of China Medical University. Only early passage cell line were used for the study. Information of patient tissues was listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

For the experiments, cells were treated with EMAP II at different concentrations (0.005 nM, 0.05 nM, 0.5 nM, and 5 nM, diluted with saline solution) for 0.5, 1, 2, 3, and 6 h, and then the medium was replaced with fresh medium for 24 h. However, cells in control group were maintained in medium containing the same concentration of saline. According to the related results, 0.05 nM and 0.5 h was considered as the optimum dosage and time, respectively. Furthermore, cells were pretreated with 2 mM 3-MA, 100 μM Z-VAD, 2 mM 3-MA+100 μM Z-VAD, 10 nM IGF-1, 500 μM TUDC, and 50 nM rapamycin in different experiments in this study.

Cell Viability Assay
--------------------

Cell viability was measured using CCK8 according to the manufacturer's instructions. The principle of the cell viability assay is that mitochondrial activity is constant for most viable cells and thereby an increase or decrease in the number of viable cells is linearly related to mitochondrial activity. CCK8 is based on the WST-8, which is reduced by dehydrogenases in the cells giving an orange colored formazan. The mitochondrial activity of the cells is reflected by the formazan. Thus, any increase or decrease in viable cell number can be detected by measuring formazan concentration. Briefly, cells were seeded in 96-well plate with 200 μl medium, incubated for 24 h under standard conditions and treated with reagents for indicated time. At the end of the time point, 20 μl of CCK8 was added to each well and incubated for additional 2 h, and the absorbance was finally measured at the wavelength of 450 nm.

JC-1 Assay for Flow Cytometry
-----------------------------

Cells were seeded in 6-well plate with 2 ml medium, incubated for 24 h and then treated with reagents for indicated time. After incubated with 10 μg/ml JC-1 at 37°C for 30 min, cells were washed once with PBS and resuspended with 500 μl PBS. The samples were immediately measured by flow cytometer. In living cells, JC-1 accumulates in mitochondria forming red fluorescent aggregates, JC-1 exists mainly in green fluorescent monomeric form once mitochondria membrane potential is depolarized. The results were analyzed by cell quest software. JC-1 green and red fluorescence was recorded on FL1 and FL2 channels, respectively. The dots distributed in the upper right quadrant (UR) and lower right quadrant (LR).

Transmission Electron Microscopy (TEM) Analysis
-----------------------------------------------

Cells were fixed with 2.5% glutaraldehyde at 4°C for 2 h and subsequently fixed with 1% OsO~4~-0.15 M Na cacodylate/HCl (pH 7.4) for 30 min. Then cells were dehydrated in graded ethanol and polymerized at 60°C for 48 h. Samples were prepared and analyzed with a JEM 1230 transmission electron microscope (JEM-1200EX; *n* = 5, each) at 60 kV. Micrographs were taken at ×5,000 or at ×10,000.

Immunofluorescence Assay
------------------------

The U87 and U118 cells were seeded on chamber slides (or GSCs were seeded on chamber slides pre-coated with fresh laminin for adherent culture) for 24 h, then treated with 0.05 nM EMAP II for 0.5 h or 0.05 nM EMAP II for indicated time. Cells were stained with LysoTracker Red at a final concentration of 50 nM, or MitoTracker Deep Red FM at a final concentration of 100 nM. Cells were fixed in 4% paraformaldehyde for 20 min, and then incubated with 5% BSA for 2 h at room temperature. Primary antibody staining was performed for LC3 (or LC3 and p62/SQSMT1). After that, cells were washed and incubated with a secondary antibody conjugated to Alexa Fluor 488 and Alexa Fluor 555. Nuclei were stained with 0.5 μg/ml DAPI. The cells were visualized using immunofluorescence microscopy (Olympus, Tokyo, Japan).

Western Blot Assay
------------------

Cells treated with reagents for indicated time were lysed in RIPA buffer supplemented with a proteinase inhibitor (10 mg/ml aprotinin, 10 mg/ml phenyl-methylsulfonyl chloride (PMSF) and 50 mM sodium orthovanadate). Cell extracts were quantified using the BCA protein assay kit and equal amounts of proteins were separated by SDS-PAGE. Gels were then transferred to PVDF membranes, blocked with 5% non-fat dry milk and incubated with the primary antibody solution. Alternatively, primary phospho-antibodies were diluted in 5% BSA in TBST overnight at 4°C. The membrane was washed with TBST and incubated with an HRP-conjugated secondary antibody solution. After subsequent washes, immunoblots were visualized by enhanced chemiluminescence (ECL kit, Santa Cruz Biotechnology). Autoradio-graphic images were scanned and integrated density value (IDV) of protein bands were quantified by ChemImager 5500 software.

Scratch Wound Healing Assay
---------------------------

Scratch wound healing assay was adapted to evaluate the migration ability of U87 and U118 cells. Briefly, cells were seeded on 6-well plates at the density of 1 × 10^4^ per well until they reached 80% confluence. Scratching wounds were created in the monolayer of confluent cells with a pipette tip. The width of wounds was assessed to be the same at the beginning of the experiments. The wells were rinsed with PBS three times to remove floating cells and debris. Cells were treated with EMAP II, rapamycin or the combination of EMAP II and rapamycin at indicated time. Wound healing was measured and recorded photographically.

Transwell Assays
----------------

The migration and invasion abilities of U87, U118, and GSCs were detected using 24-well transwell chambers with 8 μm pore size (Corning Costar). Cells were resuspended in medium and seeded on the upper chambers (without Matrigel for cell migration assay) or seeded on the upper chambers pre-coated with Matrigel (for cell invasion assay). After incubated for 24 h, the inserts were taken out and cells remained on the upper surface of the filters were removed carefully with a cotton wool swab. The migrated and invaded cells were washed with PBS and fixed with methanol and glacial acetic acid (mixed at 3:1) for 30 min at room temperature and stained using Giemsa stain for 15 min. The average number of cells was counted in six random fields.

*In Vivo* Xenograft Study
-------------------------

Four-week-old BALB/C athymic nude mice were supplied by Cancer Institute of the Chinese Academy of Medical Science. All experiments were carried out under the approval of the Administrative Panel on Laboratory Animal Care of Shengjing Hospital. All animals had access to food and water ad libitum. For subcutaneous implantation, a total of 3 × 10^5^ cells suspended in 100 μl medium was injected into the right flank regions of nude mice. Tumor volume was calculated according to the formula: volume (mm^3^) = (a × b^2^)/2 (where a is the largest superficial diameter and b is the smallest superficial diameter). When the tumors grew to about 80 mm^3^, the tumor-bearing mice were randomly assigned to the control group (treated with 0.05 nM saline), EMAP-II treatment group (treated with 80 ng/kg EMAP-II), rapamycin treatment group (treated with 50 nM rapamycin), and the combination of EMAP-II and rapamycin group (treated with 50 nM rapamycin and 80 ng/kg EMAP-II). The tumor-bearing mice were treated as described above every 12 h for 18 weeks. Tumor volume was measured every other day for 18 weeks.

Statistical Analysis
--------------------

All results were expressed as mean ± SD for each group and analyzed by use of SPSS 18.0 software. One-way ANOVA and post hoc comparisons (Bonferroni test) were utilized to determine the significant differences among multiple groups. *P* \< 0.05 was considered statistically significant.

Results
=======

Cytotoxicity of EMAP II in Human GBM Cells and GSCs
---------------------------------------------------

The effects of EMAP II on the cell viability of human GBM cells and GSCs were evaluated at indicated time and concentration (the time line of experiments was shown in **Figure [1A](#F1){ref-type="fig"}**). As shown in **Figure [1B](#F1){ref-type="fig"}**, the cell viability of U87, U118, and GSCs were inhibited by EMAP II in time- and dose-dependent patterns. Compared with the control group, the cell viability was significantly decreased at 0.5 h with the treatments of 0.05, 0.5, and 5 nM EMAP II (*P* \< 0.01). The cell viability of U87, U118, and GSCs were inhibited at 0.5, 1, and 2 h in groups of 0.05, 0.5, and 5 nM, respectively (*P* \< 0.01), whereas there was no obvious difference among three groups (*P* \> 0.05). Thus, 0.05 nM at 0.5 h were selected as the optimum concentration and time point in the subsequent experiments, respectively. We further investigated whether the inhibitory effect of EMAP II on cell viability was associated with the induced autophagy and apoptosis. Cells were pretreated with autophagy inhibitor 3-MA or caspase inhibitor Z-VAD alone or in combination. As shown in **Figure [1C](#F1){ref-type="fig"}**, the cell viability was inhibited in EMAP II and EMAP II+Z-VAD groups compared with control group (*P* \< 0.01), and there was no significant difference between these groups (*P* \> 0.05). In addition, the cell viability was increased in EMAPII+3-MA group compared with EMAP II group (*P* \< 0.01), suggesting that 3-MA blocked the inhibitory effect of EMAP II on the cell viability.

![**Effect of endothelial-monocyte activating polypeptide II (EMAP II) on human GBM cells and GSCs. (A)** Timeline of the research with EMAP II. **(B)** Effect of EMAP II on the cell viability of U87, U118, and GSCs after treatment with 0.005 nM, 0.05 nM, 0.5 nM, and 5 nM EMAP II for 0.5, 1, 2, 3, and 6 h. **(C)** Effects of EMAP II, 3-MA and Z-VAD on the cell viability of U87, U118 and GSCs after treatment with 0.05 nM EMAP-II for 0.5 h. **(D)** Effects of EMAP II, 3-MA, and Z-VAD on MMP of U87, U118, and GSCs by JC-1 staining for flow cytometry. Values represented the means ± SD (*n* = 5, each). ^∗∗^*P* \< 0.01 vs. control group, ^\#\#^*P* \< 0.01 vs. EMAP II group.](fnmol-08-00074-g001){#F1}

JC-1 staining was used to further detect the effect of EMAP II on mitochondrial membrane potential (MMP) in human GBM cells and GSCs. As shown in **Figure [1D](#F1){ref-type="fig"}**, results showed that the ratio of JC-1 monomer increased significantly and reached a peak at 0.5 h (*P* \< 0.01). Then it decreased, and finally returned to the level of control group. Since the increase of JC-1 monomer ratio is an indicator of MMP, the above result demonstrated that EMAP II decreased the MMP of U87, U118, and GSCs in a time-dependent manner (*P* \< 0.01). In addition, the ratio of JC-1 monomer in EMAP II +3-MA group was decreased compared with that in EMAP II group, suggesting that 3-MA blocked the EMAP II-induced decrease in MMP. The above results suggested that inhibitory effects of EMAP II on the cell viability and MMP might be associated with cell autophagy in human GBM cells and GSCs.

EMAP II Induced Cell Autophagy in Human GBM Cells and GSCs
----------------------------------------------------------

Due to the fact that the cell viability and MMP were not changed in cells treated with 3-MA alone, the following experiments were performed without cells treated with 3-MA alone. TEM was used to observe the effects of EMAP II on the ultrastructural changes in human GBM cells and GSCs. As shown in **Figure [2A](#F2){ref-type="fig"}**, the autophagic vacuoles were positive in U87 cells in the 0.05 nM EMAP II for 0.5 h group and negative in the control group and the EMAP II+3-MA group. The same results were also observed in U118 cells and GSCs. As shown in **Figure [2B](#F2){ref-type="fig"}**, cells were stained with anti-LC3 and LysoTracker Red by immunofluorescence. EMAP II significantly increased the punctate distribution and density of LC3 as well as autophagic vacuoles numbers in U87, U118, and GSCs (*P* \< 0.01). Co-treatment with 3-MA reduced the punctate distribution and density of LC3 as well as autophagic vacuoles numbers (*P* \< 0.01). In addition, we found that there was a significant overlap between LC3 and lysosomal signals in EMAP II treated cells (*P* \< 0.01), suggesting that autophagosome--lysosome fusion was not inhibited by EMAP II. These results suggested that EMAP II could induce autophagic vacuoles formation in human GBM cells and GSCs, and 3-MA could block this effect.

![**Effect of EMAP II and 3-MA on the ultrastructural change in human GBM cells and GSCs. (A)** Effect of EMAP II and 3-MA on the ultrastructural change in U87, U118, and GSCs. Arrows show autophagic vacuoles. **(B)** The colocalization of LC3 and LysoTracker Red in U87, U118, and GSCs. Relative mean optical density of LC3 and LysoTracker Red, and the co-localization of LC3 and LysoTracker Red quantified. Pictures are respective magnification (*n* = 4, each). Scale bar = 20 μm. ^∗∗^*P* \< 0.01 vs. control group, ^\#\#^*P* \< 0.01 vs. EMAP II group.](fnmol-08-00074-g002){#F2}

EMAP II Regulated the Expression of LC3 and p62/SQSTM1 in Human GBM Cells and GSCs
----------------------------------------------------------------------------------

Effects of EMAP II on the expression and distribution of LC3-II and p62/SQSTM1 were detected by Western blot assay and immunofluorescence assay, respectively. As shown in **Figure [3A](#F3){ref-type="fig"}**, Western blot assay was used to investigate the effects of EMAP II (0.005, 0.05, 0.5, and 5 nM) on the expression of LC3-I and LC3-II in U87, U118 and GSCs at 0.5 h. Compared with the control group, LC3-II/LC3-I expression significantly increased in 0.05, 0.5, and 5 nM EMAP II groups (*P* \< 0.01), whereas it did not change in 0.005 nM group. There was no significant difference among these three groups (*P* \> 0.05). Further, cells were treated with EMAP II (0.05 nM) at indicated time and pretreated with 3-MA to examine the LC3 and p62/SQSTM1 expression. As shown in **Figure [3B](#F3){ref-type="fig"}**, LC3-II/LC3-I expression was significantly increased at 0.5, 1, and 2 h after 0.05 nM EMAP II treatment compared with the control group (*P* \< 0.01). In addition, LC3-II/LC3-I expression was decreased in EMAPII+3-MA group compared with EMAP II group (*P* \< 0.01), suggesting that 3-MA blocked the effect of EMAP II on the LC3-II/LC3-I expression. Meanwhile, the p62/SQSTM1 expression was significantly decreased at 0.5, 1, and 2 h after 0.05 nM EMAP II treatment (*P* \< 0.01). In addition, the p62/SQSTM1 expression was increased in EMAPII+3-MA group compared with EMAP II group (*P* \< 0.01), suggesting that 3-MA blocked the inhibitory effect of EMAP II on the p62/SQSTM1 expression. The immunofluorescence assay of LC3-II and p62/SQSTM1 displayed similar results as above (**Figure [3C](#F3){ref-type="fig"}**). These results suggested that EMAP II induced cell autophagy by regulating the expression of LC3 and p62/SQSTM1 in human GBM cells and GSCs.

![**Effects of EMAP II on the expression and distribution of LC3 and p62/SQSTM1 in human GBM cells and GSCs. (A)** Western blot analysis was performed to detect the expression levels of LC3-II/LC3-I in U87, U118, and GSCs after treatment with 0.005 nM, 0.05 nM, 0.5 nM, and 5 nM EMAP II. Relative integrated density value (IDV) of LC3-II/LC3-I are shown. **(B)** Western blot analysis was performed to detect the expression of LC3-II/LC3-I and p62/SQSTM1 in U87, U118, and GSCs after treatment with 0.05 nM EMAP II for 0.5, 1, 2, 3, and 6 h, and EMAP II pretreatment with 3-MA. IDV of LC3-II/LC3-I and p62/SQSTM1 are shown. Values represented the means ± SD (*n* = 5, each). ^∗∗^*P* \< 0.01 vs. control group, ^\#\#^*P* \< 0.01 vs. EMAP II group. **(C)** The up-regulation of LC3 and down-regulation of p62/SQSTM1 in U87, U118, and GSCs were observed after treated with EMAP II alone or EMAP II plus 3-MA. Scale bar = 20 μm.](fnmol-08-00074-g003){#F3}

EMAP II Blocked the PI3K/Akt/mTOR Pathway in Human GBM Cells and GSCs
---------------------------------------------------------------------

As shown in **Figure [4A](#F4){ref-type="fig"}**, the expression of p-PI3K/PI3K and p-PI3K/GAPDH were decreased in U87, U118, and GSCs at 0.5, 1, and 2 h after 0.05 nM EMAP II treatment compared with the control group (*P* \< 0.01), and the lowest points were at 0.5 h. The expression of p-Akt/Akt, p-Akt/GAPDH, p-mTOR/mTOR, and p-mTOR/GAPDH exhibited similar results as above (**Figures [4B,C](#F4){ref-type="fig"}**). As shown in **Figure [5A](#F5){ref-type="fig"}**, compared with the control group, cells treated with 0.05 nM EMAP II at 0.5 h significantly up-regulated the LC3-II expression and down-regulated the p62/SQSTM1 expression in U87, U118, and GSCs (*P* \< 0.01). In addition, the LC3-II expression in EMAP II+IGF-1 group was decreased, whereas the p62/SQSTM1 expression in this group was increased compared with EMAP II group (*P* \< 0.01). These results suggested that IGF-1 could block the effect of EMAP II on the expression of LC3-II and p62/SQSTM1. Moreover, results from immunofluorescence assay were consistent with the above results (**Figure [5B](#F5){ref-type="fig"}**).

![**Effect of EMAP II on the expression of mTOR, PI3K, and Akt in human GBM cells and GSCs**. Western blot analysis was performed to evaluate the expression ratios of p-PI3K/PI3K, p-PI3K/GAPDH **(A)**, p-Akt/Akt, p-Akt/GAPDH **(B)**, p-mTOR/mTOR, and p-mTOR/GAPDH **(C)** in U87, U118, and GSCs treated with EMAP II for 0.5, 1, 2, 3, and 6 h. Values represented the means ± SD (*n* = 5, each). ^∗∗^*P* \< 0.01 vs. control group.](fnmol-08-00074-g004){#F4}

![**Effects of EMAP II and IGF-1 on the expression of LC3 and p62/SQSTM1 in human GBM cells and GSCs. (A)** Western blot analysis of the expression levels of LC3-II/LC3-I and p62/SQSTM1 in U87, U118, and GSCs after treatment with EMAP II, IGF-1 and their combination. IDV of LC3-II/LC3-I and p62/SQSTM1 are shown. Values represented the means ± SD (*n* = 5, each). ^∗∗^*P* \< 0.01 vs. control group, ^\#\#^*P* \< 0.01 vs. EMAP II group. **(B)** The distribution and expression of LC3 and p62/SQSTM1 in U87, U118, and GSCs. Scale bar = 20 μm.](fnmol-08-00074-g005){#F5}

EMAP II Induced Mitophagy in Human GBM Cells and GSCs
-----------------------------------------------------

Due to the MMP was affected by EMAP II, therefore we detected whether mitophagy was induced by EMAP II. As shown in **Figures [6A,B](#F6){ref-type="fig"}**, cells were stained with MitoTracker Deep Red FM and anti-LC3 by immunofluorescence, and results showed that there was a significant overlap between LC3 and MitoTracker signals in EMAP II treated cells (*P* \< 0.01), and co-treatment with 3-MA blocked this effect (*P* \< 0.01). In addition, the outer and inner mitochondrial membrane proteins (TOMM20 and TIMM23) was reduced by EMAP II, and co-treatment with 3-MA rescued the inhibitory effect induced by EMAP II (**Figures [6C--E](#F6){ref-type="fig"}**).

![**EMAP II induced mitophagy in human GBM cells and GSCs. (A)** The colocalization of LC3 and MitoTracker in U87, U118, and GSCs after cells treated with EMAP II and the combination of EMAP II and 3-MA. **(B)** Quantitative analysis of the co-localization of LC3 with MitoTracker. Pictures are respective magnification (*n* = 4, each). Scale bar = 20 μm. Western blot analysis of the expression of TOMM20 and TIMM23 in U87 **(C)**, U118 **(D)** and GSCs **(E)** after cells treated with EMAP II and the combination of EMAP II and 3-MA. Values represented the means ± SD (*n* = 5, each). ^∗∗^*P* \< 0.01 vs. control group, ^\#\#^*P* \< 0.01 vs. EMAP II group.](fnmol-08-00074-g006){#F6}

EMAP-II Induced the Activation of Endoplasmic Reticulum (ER) Stress in Human GBM Cells and GSCs
-----------------------------------------------------------------------------------------------

Several studies reported that autophagy could be induced by unfolded protein response (UPR) which is the major endoplasmic reticulum (ER) stress pathway ([@B50]). To examine whether ER stress was induced by the EMAP-II treatment, levels of the UPR-related proteins GRP78, p-eIF2α, eIF2α, and CHOP were measured after cells treated with 0.05 nM EMAP II for 0.5 h, (TUDC, an ER stress inhibitor) or their combination. As shown in **Figure [7A](#F7){ref-type="fig"}**, the expression of GRP78, p-eIF2α, and CHOP were increased in EMAP II group compared with the control group in U87 cells (*P* \< 0.01). In addition, the expression of GRP78, p-eIF2α, and CHOP were decreased in the combination of EMAP II with TUDC group compared with the EMAP II group (*P* \< 0.01). The similar results were also observed in U118 cells and GSCs (**Figures [7B,C](#F7){ref-type="fig"}**). These results suggested that human GBM cells and GSCs exposed to EMAP-II experienced ER stress.

![**Effects of EMAP II and tauroursodeoxycholate (TUDC) on the expression of UPR-related proteins in human GBM cells and GSCs**. Western blot analysis of the expression of GRP78, p-eIF2α, eIF2α, and CHOP in U87 **(A)**, U118 **(B),** and GSCs **(C)** after treatment with EMAP II, TUDC and their combination. Values represented the means ± SD (*n* = 5, each). ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 vs. control group, ^\#\#^*P* \< 0.01 vs. EMAP II group.](fnmol-08-00074-g007){#F7}

The Combination of EMAP II with Rapamycin Inhibited Cell Proliferation, Migration, and Invasion of Human GBM Cells and GSCs
---------------------------------------------------------------------------------------------------------------------------

The abilities of cell proliferation, migration and invasion were investigated to further evaluate the effects of the combination of EMAP II with rapamycin on the biological behaviors of human GBM cells and GSCs. As shown in **Figure [8A](#F8){ref-type="fig"}**, compared with the control group, the cell proliferation of U87, U118, and GSCs were inhibited after EMAP II or rapamycin treatment (*P* \< 0.01). The cell proliferation of U87, U118, and GSCs was more remarkably inhibited by the combination of EMAP II with rapamycin compared with the use of either agent alone (*P* \< 0.05). As shown in **Figure [8B](#F8){ref-type="fig"}**, scratch wound healing assay showed that the migration of U87 and U118 cells in EMAP II or rapamycin groups were inhibited compared with that in the control group (*P* \< 0.01). In addition, EMAP II in combination with rapamycin displayed even greater inhibitory effect on the migration of U87 and U118 cells than either EMAP II or rapamycin alone (*P* \< 0.05). Subsequently, we employed the transwell migration assay to further define the migration of U87, U118 and GSCs, and the results were similar as above (**Figure [8C](#F8){ref-type="fig"}**). As shown in **Figure [8D](#F8){ref-type="fig"}**, the invasion of U87, U118, and GSCs in EMAP II or rapamycin groups were inhibited compared with that in the control group (*P* \< 0.01). EMAP II in combination with rapamycin displayed even greater inhibitory effect on the invasion of U87, U118, and GSCs than either EMAP II or rapamycin alone (*P* \< 0.05). The above results suggested that the combination of EMAP II with rapamycin inhibited the malignant biological behaviors of human GBM cells and GSCs.

![**Effects of EMAP II and rapamycin on the cell proliferation, migration, and invasion of human GBM cells and GSCs. (A)** Cell proliferation of U87, U118, and GSCs was assessed by CCK8 assay. **(B)** The migration of U87 and U118 cells was measured by wound healing assay. **(C)** Cell migration of U87, U118, and GSCs was measured by transwell assay. **(D)** Cell invasion of U87, U118, and GSCs was measured by transwell assay. Values represented the means ± SD (*n* = 5, each). ^∗∗^*P* \< 0.01 vs. control group; ^\#^*P* \< 0.05 vs. EMAP II group; ^Δ^*P* \< 0.05 vs. rapamycin group.](fnmol-08-00074-g008){#F8}

The Combination of EMAP II with Rapamycin Produced the Smallest Tumors *In Vivo*
--------------------------------------------------------------------------------

The growth-inhibitory effects of EMAP-II and rapamycin were further tested in xenografted mice. Representative images of mice and tumors were shown in **Figures [9A,B](#F9){ref-type="fig"}**. Tumor growth was significantly suppressed in nude mice treated with EMAP-II, rapamycin or the combination of EMAP II with rapamycin compared with that in the control group (*P* \< 0.01). Combined treatment of EMAP II with rapamycin produced further inhibition on tumor growth than EMAP-II or rapamycin group (*P* \< 0.05) (**Figures [9C,D](#F9){ref-type="fig"}**). These results showed that nude mice carrying human GBM cells and GSCs which were treated with the combination of EMAP II with rapamycin produced the smallest tumors.

![**The *in vivo* study of EMAP II and rapamycin**. Representative images of mice **(A)** and tumors **(B)** obtained from the xenografted mice with or without treatment for 18 weeks. **(C)** Tumor growth curve in nude mice. **(D)** Tumor weight in nude mice. ^∗∗^*P* \< 0.01 vs. control group, ^\#^*P* \< 0.05 vs. EMAP-II group, ^Δ^*P* \< 0.05 vs. rapamycin group.](fnmol-08-00074-g009){#F9}

Discussion
==========

In the present study, we found that low-dose EMAP II inhibited the cell viability and MMP in human GBM cells and GSCs by inducing autophagy, accompanied by the up-regulation of LC3-II and the down-regulation of p62/SQSTM1. Moreover, we provided the evidence that cells treated with EMAP-II inhibited the PI3K/Akt/mTOR signal pathway, and experienced mitophagy and ER stress. Finally, the combination of EMAP II and rapamycin showed the inhibitory effect on the cell proliferation, migration, and invasion of GBM cells and GSCs *in vitro* and *in vivo*.

Endothelial-monocyte activating polypeptide II has been recognized as an angiostatic mediator that suppresses neovascularization, induced endothelial cell apoptosis, inhibited tumor vessel formation, and suppressed primary and metastatic tumor growth ([@B38]; [@B4]). In addition, EMAP II was found to reduce the proliferation of tumor cells within the neoplastic tissue ([@B41]). Our results showed that low-dose EMAP II significantly inhibited the cell viability of human GBM cells and GSCs at 0.5 h. To further analyze the possible mechanisms, cells were pretreated with autophagy inhibitor 3-MA or broad-spectrum caspase inhibitor Z-VAD. Our results showed that only 3-MA blocked the inhibitory effect of EMAP II on the cell viability. It has been reported that EMAP II inhibited the growth of endothelial cells and pancreatic cancer cells, and the inhibitory effect was associated with the inhibition of tumor vascular endothelium growth ([@B41]). However, the underlying mechanism in regarding to this inhibition may involve many aspects, such as EMAP II inhibited the growth of pancreatic cancer through inhibiting fibronectin-dependent proliferation ([@B39],[@B40]) or inhibited tumor angiogenesis by inducing endothelial cell apoptosis ([@B4]). However, the dose of EMAP II described in our present study has not been reported to induce apoptosis in GBM cells and GSCs. Mitochondrial functional status is closely related to cancerogenesis, and MMP is one of the important parameters of mitochondrial functional status. Our results showed that EMAP II decreased the MMP and formed a trough at 0.5 h. Meanwhile, EMAP II-induced MMP inhibition was blocked by 3-MA, indicating that EMAP II inhibited cell viability and impaired the mitochondrial function might be associated with autophagy. Additionally, we observed the existence of autophgosomes and the increased punctate distribution of LC3 under the treatment of 0.05 nM EMAP II for 0.5 h, and 3-MA blocked this effect. Thus, our results demonstrated that the cytotoxicity of EMAP II in human GBM cells and GSCs was induced by autophagy. Moreover, mitochondria have been described as a source of autophagosome biogenesis, and plays a key role in the cross-talk between autophagy and apoptosis regulation ([@B17]; [@B47]). Mitophagy is a process through which dysfunctional mitochondria are selectively removed by autophagy ([@B20]). Our results showed that EMAP II induced mitophagy in human GBM cells and GSCs, suggesting that the mitophagy might be involved in the cytotoxicity induced by EMAP II.

LC3, an autophagy marker, exists in cells in two forms: LC3-I and LC3-II. As a marker of autophgosomes, the expression level of LC3-II reflects the number of autophgosomes to a certain extent ([@B24]). Our study revealed that EMAP II significantly increased LC3-II expression at the concentrations of 0.05, 0.5, and 5 nM. The expression of LC3-II was increased to peak level at 0.5 h under the treatment of 0.05 nM EMAP II with the punctuate of LC3 aggregated in GBM cells and GSCs. P62/SQSTM1 is a multifunctional ubiquitinated protein coupled to LC3, which is involved in the formation of autophgosomes as a regulatory factor and is degraded in the middle or late phase of autophagy. Therefore, the total expression level of intracellular p62/SQSTM1 was negatively correlated with autophagic activity ([@B5]). Consistent with the above study, the effect of EMAP II on the p62/SQSTM1 expression was opposite to LC3-II. P62/SQSTM1 plays important roles in the regulation of intracellular autophagy, proteasome and NF-κB signaling pathway. It has been reported that the repression of autophagy led to over-expression of p62/SQSTM1, which promoted tumor cell proliferation by various mechanisms such as regulating NF-κB signaling pathway, the accumulation of oxygen radicals, DNA damage and other processes ([@B22]; [@B28]).

PI3K/Akt/mTOR signal pathway is mainly involved in regulating cell growth, apoptosis and other important cellular signal transduction ([@B9]; [@B58]). Furthermore, PI3K/Akt/mTOR is a critical regulatory pathway in autophagy response ([@B48]; [@B15]). Recent study revealed that PI3K/Akt/mTOR signal pathway would be commonly activated in human glioma cells ([@B35]; [@B43]; [@B56]). To further investigate the possible mechanism involved in this process, we studied the effect of EMAP II on P13K, Akt, and mTOR signal molecules. Our study found that the PI3K/Akt/mTOR signal pathway was inhibited at 0.5, 1, and 2 h after 0.05 nM EMAP II treatment, and the PI3K/Akt agonist IGF-1 significantly blocked the effect of EMAP II on the expression of LC3-II and p62/SQSTM1, suggesting the EMAP-II-induced autophagy is dependent of PI3K/Akt/mTOR signal pathway. The effect of some anti-neoplastic drugs are also associated with the regulation of PI3K/Akt/mTOR signal pathway. Chlorpromazine was reported to induce autophagic cell death in U87 cells through inhibiting Akt/mTOR ([@B43]). The inhibition of mTOR cascade reaction pathway was also involved in the synergistic anti-glioma effect of niclosamide in combination with emozolomide ([@B48]).

The endoplasmic reticulum (ER) is responsible for protein folding, lipid and sterol biosynthesis, and intracellular calcium storage ([@B37]). Accumulation of unfolded proteins in the ER, nutrient deprivation, calcium imbalance, oxidative stress, metabolic alterations, and environmental acidity activate UPR signaling to enable adaptation to perturbations and to relieve ER stress by activating three ER-resident transmembrane transducers ([@B21]; [@B7]). Autophagy could supplement cellular metabolism by digesting damaged organelles or misfolded proteins. In addition, recent studies have confirmed that ER stress is a potent inducer of autophagy ([@B10]; [@B42]), thus the levels of the UPR-related proteins GRP78, p-eIF2α, eIF2α, and CHOP were measured. Our results showed that the expression of GRP78, p-eIF2α, and CHOP were increased in EMAP II group, TUDC attenuated the expression of these induced by EMAP II, suggesting that cells exposed to EMAP-II experienced ER stress. In addition, we have demonstrated that EMAP II induced cell autophagy in human GBM cells and GSCs, suggesting that autophagy induced by EMAP-II might be related with ER stress.

Rapamycin, an mTOR inhibitor, is widely used in the experimental and clinical researches for anti-neoplastic drugs ([@B32]; [@B53]). The mTOR inhibitors have been used in the clinical trial for several tumors, among them are rapamycin analogs temsirolimus and everolimus which have been used to treat some tumors ([@B23]; [@B12]; [@B52]). In the study of glioma treatment, everolimus led to cell cycle arrest and increased radiosensitivity in malignant glioma cells by activating autophagy response ([@B36]). Therefore, we further evaluated the effects of EMAP II alone or in combination with rapamycin on the biological behaviors of human GBM cells and GSCs. Our results showed that both EMAP II and rapamycin significantly inhibited the cell proliferation, migration, and invasion of human GBM cells and GSCs. The combination of these two agents displayed more inhibitory effect on the malignant behavior of these cells. The *in vivo* studies also showed that the combination of EMAP II with rapamycin produced the smallest tumors. In line with our study, previous study have shown that rapamycin could inhibit the proliferation of glioma cells by inducing autophagy ([@B6]), which contributed to the anti-glioma effect of EMAP II combined with rapamycin.

As mentioned above, our study illustrated that the cytotoxicity of low-dose EMAP II in human GBM cells and GSCs was induced by autophagy, accompanied by the inhibition of PI3K/Akt/mTOR signal pathway, mitophagy and ER stress. Furthermore, EMAP II combined with rapamycin significantly inhibited cell proliferation, migration and invasion of human GBM cells and GSCs. Thus, the combined therapy of EMAP II with agents that can inhibit P13K/Akt/mTOR signal pathway may be a new novel therapeutic strategy for the treatment of human glioblastoma.
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